Shanghai Sunve Pharmaceutical Co., Ltd. is a pharmaceutical company established in 1958, as a major member of Business Unit of APIs & Intermediates of Shanghai Pharm. Sunve is specially and professionally engaged in research, development, regulatory affairs, production, contract manufacture, marketing and sales of APIs and Drugs.

        Sunve has turned out more than 100 kinds of products including APIs, drugs (oral solid dosage), intermediates, health care products etc., mainly for anti-infection, cardiavascular, CNS, antipyretic & analgesic, vitamins etc. And, over 80% of total APIs are exported to more than 50 countries and regions in Asia, Europe and America, which reaches top rank of exports in Chinese pharmaceutical industry. Sunve is a major enterprise of Shanghai Municipal Development Program of Modern Bioengineering and Pharmaceutical Industry, and is defined as a Shanghai Municipal High-Tech Enterprise. 

        Sunve has established strict and fully total QA/QC system for all products. All facilities are in complying with current GMP of China and US. The products' quality could reach the standards of the latest editions of ChP, USP, BP, JP etc. The following APIs have approved by US FDA, including Sulfadiazine (SD), Sulfathiazole (ST), Sulfadimethoxine (SDM), Sulfadimidine Sodium (SM2-Na), Ormetoprim (OMP), Sulfaquinoxaline(SQ), Sulfaquinoxaline Sodium (SQ),  Sulfamerazine Sodium (SM1-Na), Florfenicol (FFC) and Gemfibrozil.